Integer Holdings Corporation (ITGR)

Stock NYSE

$126.75

+0.11 (+0.09%)

Delayed quote.

Price history

Daily close
ITGR daily closing price, Nov 6, 2025 to Nov 5, 2026 Closed at $66.64 on Nov 6, 2025 and $126.75 on Nov 5, 2026, a change of +90.20%. Range $66.64 to $126.75.
Daily closes, Nov 6, 2025 to Nov 5, 2026 (251 trading days).
Start
$66.64
Latest close
$126.75
Period change
+90.20%
Period low
$66.64
Period high
$126.75

Key metrics

Market cap
$4.31B
Volume
1.01M
Average volume
936.1K
52-week range
$66.00 – $126.83
Beta
0.58
Last dividend
—
EPS (TTM)
$3.00
P/E ratio
42.25
Revenue (TTM)
$1.82B
Net income (TTM)
$103.70M
Total assets
$3.39B
Total debt
$1.34B
Cash and equivalents
$14.13M

Key financials (trailing twelve months).

Company profile

Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.

Sector
Healthcare
Industry
Medical - Devices
Exchange
NYSE
CEO
Payman Khales
Employees
11,000
Headquarters
Plano, TX, US
IPO date
2000-09-29

Financial statements

Annual, last 3 fiscal years. Most recent period first. Reported in USD.

Income statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Revenue$1.85B$1.72B$1.56B
Gross profit$425.81M$461.18M$411.52M
Operating income$209.27M$208.24M$163.32M
EBITDA$298.38M$334.26M$277.56M
Net income$102.76M$119.90M$90.65M
Diluted EPS$2.89$3.40$2.69
Balance sheet
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Cash and equivalents$17.16M$46.54M$23.67M
Total assets$3.41B$3.08B$2.94B
Total liabilities$1.66B$1.46B$1.42B
Total debt$1.40B$1.10B$1.05B
Shareholders’ equity$1.75B$1.62B$1.52B
Cash flow statement
MetricFY2025Dec 31, 2025FY2024Dec 31, 2024FY2023Dec 31, 2023
Operating cash flow$196.15M$205.21M$180.21M
Capital expenditure-$91.03M-$105.36M-$119.94M
Free cash flow$105.12M$99.85M$60.27M

Quarterly, last 6 quarters. Most recent period first. Reported in USD.

Income statement
MetricQ3 2026Oct 2, 2026Q2 2026Jul 3, 2026Q1 2026Apr 3, 2026Q4 2025Dec 31, 2025Q3 2025Sep 26, 2025Q2 2025Jun 27, 2025
Revenue$449.66M$464.11M$439.58M$470.89M$466.57M$472.83M
Gross profit$101.56M$112.94M$109.59M$106.10M$108.29M$107.29M
Operating income$28.21M$34.53M$35.16M$51.11M$53.60M$52.70M
EBITDA$61.56M$67.96M$65.10M$91.57M$88.40M$87.51M
Net income$14.98M$23.61M$16.51M$48.61M$39.68M$37.01M
Diluted EPS$0.43$0.69$0.48$1.38$1.11$1.04
Balance sheet
MetricQ3 2026Oct 2, 2026Q2 2026Jul 3, 2026Q1 2026Apr 3, 2026Q4 2025Dec 31, 2025Q3 2025Sep 26, 2025Q2 2025Jun 27, 2025
Cash and equivalents$14.13M$21.38M$8.12M$17.16M$58.94M$23.14M
Total assets$3.39B$3.42B$3.41B$3.41B$3.40B$3.37B
Total liabilities$1.67B$1.70B$1.71B$1.66B$1.65B$1.67B
Total debt$1.34B$1.36B$1.38B$1.40B$1.31B$1.32B
Shareholders’ equity$1.73B$1.72B$1.70B$1.75B$1.75B$1.70B
Cash flow statement
MetricQ3 2026Oct 2, 2026Q2 2026Jul 3, 2026Q1 2026Apr 3, 2026Q4 2025Dec 31, 2025Q3 2025Sep 26, 2025Q2 2025Jun 27, 2025
Operating cash flow$36.63M$59.73M$24.70M$55.41M$65.59M$43.86M
Capital expenditure-$20.53M-$22.69M-$23.96M-$27.48M-$19.34M-$19.00M
Free cash flow$16.10M$37.04M$737.0K$27.94M$46.26M$24.86M